Get the Stockscreener App
27.73
1.91%
-0.53
Catalyst Pharmaceuticals Inc stock is traded at $27.73, with a volume of 679.57K.
It is down -1.91% in the last 24 hours and up +16.57% over the past month.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
See More
Previous Close:
$28.26
Open:
$28.26
24h Volume:
679.57K
Relative Volume:
0.49
Market Cap:
$3.38B
Revenue:
$588.99M
Net Income/Loss:
$214.33M
P/E Ratio:
16.46
EPS:
1.6844
Net Cash Flow:
$208.61M
1W Performance:
+0.15%
1M Performance:
+16.57%
6M Performance:
+32.19%
1Y Performance:
+14.12%
1-Day Range:
$27.68
$28.49
1-Week Range:
$26.50
$32.56
52-Week Range:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
27.71 | 3.60B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
429.62 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
706.58 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.18 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
315.84 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
296.49 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma - MSN
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 - The Manila Times
Catalyst posts Q1 results after the bell May 11; call set for 8:30 ET - Stock Titan
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Angelini Pharma Considers Acquisition of Catalyst Pharmaceuticals (CPRX) - GuruFocus
BofA reiterates Catalyst Pharmaceuticals stock rating on M&A report By Investing.com - Investing.com Canada
Italy’s Angelini said to explore Catalyst Pharma acquisition - MSN
Catalyst Pharmaceuticals (CPRX) Shares Surge on Acquisition Inte - GuruFocus
Catalyst Pharmaceuticals jumps on report of potential acquisition interest - Quiver Quantitative
Italy’s Angelini Said to Explore Catalyst Pharma Acquisition - Bloomberg
Italy's Angelini said to explore acquisition of Catalyst PharmaBloomberg News - marketscreener.com
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma (CPRX:NASDAQ) - Seeking Alpha
Catalyst Pharmaceuticals stock surges on takeover report By Investing.com - Investing.com Canada
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
Italy’s Angelini Said to Explore Acquisition of Catalyst Pharma - Bloomberg.com
Catalyst Pharmaceuticals Jumps 6.8% Amid Sector-Wide Rally - AlphaStreet
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution - Sahm
Should Stronger Firdapse and Agamree Momentum Require Action From Catalyst Pharmaceuticals (CPRX) Investors? - Sahm
How Rare-Disease Drug Momentum At Catalyst Pharmaceuticals (CPRX) Has Changed Its Investment Story - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived - Pharmaceutical Executive
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - TradingView
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Catalyst Pharmaceuticals stock hits all-time high at $26.63 - Investing.com
Is Catalyst (CPRX) stock attracting cautious sentiment | Q4 2025: Better Than ExpectedReal Time Stock Idea Network - Xã Thanh Hà
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
The Bull Case For Catalyst Pharmaceuticals (CPRX) Could Change Following Firdapse Exclusivity Win And Agamree Launch - Sahm
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Strong Buy" from Brokerages - MarketBeat
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
Price-Driven Insight from (CPRX) for Rule-Based Strategy - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Is Up 5.3% After Stronger Revenue And Expanded M&A PipelineWhat's Changed - Sahm
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Institutional Support And Deal Pipeline Shape Outlook For Catalyst Pharmaceuticals - Yahoo Finance
Theravance Stock Declines Around 17% in Three Months: Here's Why - TradingView
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know - TradingView
See How Institutions Boost Catalyst Shares - Yahoo Finance Australia
Best Momentum Stock to Buy for March 4th - Eastern Progress
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Strength - Yahoo Finance
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup - ChartMill
If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now - MSN
Gains Recap: Is Catalyst Pharmaceuticals Incs growth already priced inMarket Trend Report & Verified Technical Signals - baoquankhu1.vn
Jim Cramer on Catalyst Pharmaceuticals: "It's a very inexpensive stock" - MSN
SG Americas Securities LLC Has $765,000 Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):